PLoS ONE (Jan 2022)

The clinical value of miRNA-21 in cervical cancer: A comprehensive investigation based on microarray datasets.

  • Zhi-Min Deng,
  • Gan-Hong Chen,
  • Fang-Fang Dai,
  • Shi-Yi Liu,
  • Dong-Yong Yang,
  • An-Yu Bao,
  • Yan-Xiang Cheng

DOI
https://doi.org/10.1371/journal.pone.0267108
Journal volume & issue
Vol. 17, no. 4
p. e0267108

Abstract

Read online

Previous work has demonstrated that the expression of microRNA-21 (miR-21) is implicated in cervical cancer (CC). However, little is known regarding its associations with clinical parameters. We first conducted a meta-analysis using data from Gene Expression Omnibus (GEO) microarrays and The Cancer Genome Atlas (TCGA). Then, enrichment analysis and hub gene screening were performed by bioinformatic methods. Finally, the role of the screened target genes in CC was explored. According to the meta-analysis, the expression of miR-21 in cancer tissues was higher than in adjacent nontumor tissues (P < 0.05). In addition, 46 genes were predicted as potential targets of miR-21. After enrichment analyses, it was detected that these genes were enriched in various cancer pathways, including the phosphatidylinositol signaling system and mammalian target of rapamycin (mTOR) signaling pathway. In this study, bioinformatic tools and meta-analysis validated that miR-21 may function as a highly sensitive and specific marker for the diagnosis of CC, which may provide a novel approach to the diagnosis and treatment of CC.